CSI Market
Sign In | Register

Coya Therapeutics Inc (COYA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access COYA Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Coya Therapeutics Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-13.85
Depreciation & amortization0.01
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue-0.49
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation3.14
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
In Process Research And Development0.01
Increase Decrease In Collaboration Receivable-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-0.10
Increase (Decrease) in Accrued Liabilities-1.54
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.64
Other Working Capital0.12
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.51
Discontinued operations0.00
Net Cash flow from Operating Activities-13.58
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire Fixed Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development-0.89
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.89
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.12
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock10.95
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payment Of Deferred Financing Costs Related To Initial Public Offering-
Proceeds From Founders For Subscription Receivable-
Proceed From Sale Of Common Stock From Private Placement Net Of Offering Cost-
Proceeds From Subscription Receivable-
Payment Of Financing Costs Related To Private Placement-
Proceeds From Sale Of Common Stock From Private Placement Net Of Offering Cost-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities10.83
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-13.58
Total Cash Flow-3.64
4 historic quarters locked

Sign in to unlock the full Coya Therapeutics Inc cash flow history.

Sign In Create Free Account

About Coya Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-343481

Figures are derived from filed reports and may be restated. Historical data is subject to revision.